Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + vintafolide
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
Paclitaxel + vintafolide is an investigational combination therapy composed of two agents: - **Paclitaxel** is a well-established chemotherapeutic agent that stabilizes microtubules and inhibits cell division, leading to apoptosis in rapidly dividing cancer cells. - **Vintafolide** (EC145) is a folate receptor-targeted small molecule drug conjugate. It consists of a folic acid ligand linked to desacetylvinblastine hydrazide (DAVLBH), a potent vinca alkaloid cytotoxic agent. Vintafolide selectively binds to the folate receptor alpha, which is overexpressed on certain tumor cells (notably ovarian and some breast cancers), allowing targeted delivery of the cytotoxic payload. The rationale for combining these drugs lies in their non-overlapping toxicity profiles and potential synergistic antitumor effects. Preclinical studies have shown enhanced efficacy when used together compared to either agent alone[2]. Clinical trials have evaluated this combination in advanced triple-negative breast cancer and other solid tumors expressing the folate receptor[1][6][8].
- Other names
- vintafolide and paclitaxel
02
Targets
FOLR1 (FRα)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + vintafolide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + vintafolide.